This section contains the latest highlighted research for patients from ASCO medical journals, including the Journal of Clinical Oncology, as well as an archive of research highlights from previous ASCO scientific meetings (2011-2015). For the latest research highlights from more recent ASCO meetings, visit the Cancer.Net Blog or check out Cancer.Net’s audio podcasts and videos for patients.
To search this archive, use the drop-down menu below. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
A new clinical trial showed that the drug called radium-223 chloride (Ra-223), designed to treat bone metastases (cancer that has spread to the bone), helps men with metastatic castration-resistant prostate cancer live longer and slows the development of bone problems from the cancer. Castration-resistant prostate cancer is when the cancer continues to grow and spread without needing the male sex hormone testosterone.
A new drug was shown to help men with metastatic prostate cancer live longer in a recent clinical trial. Metastatic prostate cancer is cancer that has spread outside the prostate and is often difficult to treat. The drug called MDV3100 was designed to prevent male sex hormones called androgens, such as testosterone, from helping the cancer grow and spread.
A new study showed that men with early-stage prostate cancer who exercise vigorously at least three hours a week have genes that are expressed differently in the prostate than those who do not exercise as intensely. Genes are small individual collections of information within each cell of the human body. How these genes affect the body is called gene expression.
The researchers found that a little more than 7% of men who received external-beam radiation therapy experienced side effects, such as narrowing of the urethra and bleeding in the bladder, compared with a little less than 7% of men who received a prostatectomy and about 3% of men who had brachytherapy. In addition, men who had external-beam radiation therapy were much more likely to experience gastrointestinal side effects, such as bleeding from the rectum. The researchers also found that external-beam radiation therapy was more than twice as expensive as brachytherapy or prostatectomy.
Researchers found that the targeted therapy regorafenib lengthens the lives of patients with metastatic colorectal cancer (colorectal cancer that has spread outside the colon and rectum) and slows the growth of the cancer. Targeted therapy is a treatment that targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
A new study shows that a specific test can help find which people with Barrett's esophagus have a higher risk of esophageal cancer. Barrett's esophagus is a condition associated with abnormal changes (called dysplasia) in the cells lining the esophagus. These changes are not cancerous, but they can become cancerous over time as the cells become more abnormal. Although all people with Barrett's esophagus are at risk for esophageal cancer, there has been no good way to find out who is more likely to develop cancer.
In a new analysis of results from a previous study, researchers found that certain factors predict whether an advanced neuroendocrine tumor will worsen. Based on these factors, the drug everolimus (Afinitor) combined with octreotide (Sandostatin) may be a more effective treatment than previously thought. A neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is a cross between hormone-producing cells and nerve cells.
Researchers used a new blood test that correctly identified the presence of early-stage pancreatic cancer in two-thirds of patients participating in this study. The test detects a specialized protein, called PAM-4, in a person's blood. PAM-4 is a tumor marker, which is a substance found at higher than normal levels in the blood, urine, and body tissues of people with cancer. Developing a test for pancreatic cancer is important because patients have a better chance of survival when pancreatic cancer is found early. Currently, there is no test approved by the U.S. Food and Drug Administration to detect and diagnose pancreatic cancer early.
A large, retrospective study has shown that children of childhood cancer survivors who received prior treatment involving radiation to testes or ovaries and/or chemotherapy with alkylating agents do not have an increased risk for birth defects compared to children of survivors who did not have such cancer treatment. Radiotherapy and chemotherapy with alkylating agents are DNA-damaging treatments, affecting both cancer and healthy cells. The findings provide reassurance that increased risks of birth defects are unlikely for cancer survivors who are concerned about the potential effects of their treatment on their children, and help guide family planning choices.
An analysis of more than 3,000 families including women with breast cancer has found that close relatives of women who carry mutations in a BRCA gene - but who themselves do not have such genetic mutations - do not have an increased risk of developing breast cancer compared to relatives of women with breast cancer who do not have such mutations.